Bringing automated insulin optimization to the 85% of insulin users who inject.
Works with your connected insulin pen and CGM.
Millions of people who inject insulin still are unable to control their glucose levels.
DreaMed is changing that.
-
DreaMed technology is incorporated into Medtronic MiniMed™ 780G.
-
Commercial partnership with Abbott.
-
FDA review underway
Works with your connected insulin pen and CGM.
Thank you for your interest in DreaMed.
I would be honored to share with you DreaMed’s mission and to briefly explain why I believe automated insulin optimization for users who inject insulin represents one of the largest remaining opportunities in diabetes.
Eran Atlas
Co-Founder & CEO, DreaMed Diabetes
I'd be happy to share more details and answer your questions in a short call.
Why Investors Are Paying Attention
1.
A Massive Unmet Market
- 85% of insulin users rely on injections
- 6.7M have uncontrolled glucose in the US
- $7.3B avoidable annual US healthcare costs
2.
Proven Execution
- Algorithm technology used in Medtronic MiniMed 780G
- 1 De Novo approval
- 5 510(k) clearances
3.
Commercial Validation
- Abbott Development and Commercialization Agreement
- Medtronic acquisition of Companion Medical (Inpen)
- Novo Nordisk acquisition of Biocorp
See the full investment opportunity
-
Algorithm development proven
-
-
Medtronic commercial success
-
-
Clinical validation
-
-
Abbott partnership
-
-
FDA review underway
-
-
Commercial launch